Navigation Links
Indevus Reports Positive Data From Phase III NEBIDO Trial

Compound Achieves All Key Endpoints for Both Efficacy and Safety

LEXINGTON, Mass., June 07, 2007 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. today announced final results from its Phase III pharmacokinetic trial for NEBIDO (testosterone undecanoate), a long- acting injectable testosterone therapy under development for the treatment of male hypogonadism which the Company licensed from Bayer Schering Pharma AG, Germany. The data from the recently completed 48-week trial showed that NEBIDO met its primary endpoints, a responder analysis based on average testosterone concentrations during the steady state dosing interval and an outlier analysis based on the maximum testosterone concentrations during the steady state dosing interval. In addition, the drug was well tolerated. The Company will host a conference call and webcast today at 9:00 a.m. eastern time (details follow below).

"I am extremely pleased to report the successful completion of our NEBIDO study and we are looking forward to the submission of our NDA later this summer," stated Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "The market opportunity for NEBIDO is substantial. The results of our trial demonstrate the potential of NEBIDO, the only once every three month treatment for male hypogonadism, to dramatically improve the treatment options for men who suffer from this condition."

Study Design

The study was designed to supplement the European clinical trial database (originally generated by Bayer Schering Pharma AG, Germany), which has formed the basis for the approval of NEBIDO in over 75 countries to date. Specifically, the purpose of the completed Phase III trial was to evaluate NEBIDO under U.S. Food and Drug Administration (FDA) pharmacokinetic guidelines for the approval of testosterone therapy products for male hypogonadism.

The Phase III pharmacokinetic trial was a randomized op
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Indevus Announces Presentation of Pagoclone Data at 47th Annual New Clinical Drug Evaluation Unit Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Indevus Reports Positive Data From Phase III NEBIDO Trial
(Date:4/21/2015)... YORK , April 21, 2015 EpiCast ... Summary Sepsis is a life-threatening complication arising from ... the infection damages its own tissues and organs. Anyone ... among children <1 year of age, older ... 2014). Global estimates for the year 2013 showed that ...
(Date:4/21/2015)... -- Inmark,s acquisition of Saf-T-Pak last week positioned Inmark ... Division 6.2.  For over 25 years, Saf-T-Pak has ... on IATA, ICAO, US DOT, Transport Canada, RID/ADR ... were particularly interested in Saf-T-Pak,s proprietary Learning Management ... programs," said David Oyler , Inmark President ...
(Date:4/21/2015)... , 21. April 2015  CorTechs ... die quantitative Analyse des Hirnvolumens freut sich, ... weltweiten Pharmaunternehmen, bekannt geben zu können. Die ... NeuroQuant-Quantifizierungsreports des Hirnvolumens zusammenarbeiten, der die Identifizierung, ... in Patienten mit multipler Sklerose als Ziel ...
Breaking Medicine Technology:EpiCast Report: Sepsis - Epidemiology Forecast to 2023 2EpiCast Report: Sepsis - Epidemiology Forecast to 2023 3Inmark's Acquisition Of Saf-T-Pak Results In Expansion Of Its Dangerous Goods Training Portfolio 2CorTechs Labs kündigt Partnerschaft für die Bereitstellung umfassender Lösungen zur Quantifizierung des Verlustes von Hirnvolumen bei multipler Sklerose an 2
(Date:4/21/2015)... Danvers, MA (PRWEB) April 21, 2015 ... managed mobility services, has been recognized by the Boston ... Massachusetts. The ranking was announced at a recent ... Journal’s annual list of the fastest-growing private companies in ... held businesses in the state that recorded the fastest ...
(Date:4/21/2015)... The report “Dermatitis – ... on the therapeutic development for Dermatitis. ... new targets and MOAs to produce first-in-class ... is available @ http://www.rnrmarketresearch.com/dermatitis-pipeline-review-h1-2015-market-report.html . ... involved in the therapeutic development for Dermatitis ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 Edward ... and Arthur “A.G.” Kawamura, former Secretary of the California ... featured speakers for the 2nd Annual GrowRIVERSIDE Conference: The ... , The inclusion of these nationally known experts ... experts, city planners, farmers and others slated to speak ...
(Date:4/21/2015)... Chicago, IL (PRWEB) April 21, 2015 ... the online retailer known for innovation at its healthiest, ... supplements starting May 1st. , At Wojo Nutrition, they’ve ... health seekers with convenient solutions tailored to meet their ... designed to be blended with any beverage, has been ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Carinsuranceshoppingsource.com ... of analyzing comprehensive auto insurance plans . ... it provides coverage for numerous situations. The coverage limit ... expensive. Comprehensive auto insurance will protect a car against ... , Comparing quotes is no longer difficult and ...
Breaking Medicine News(10 mins):Health News:Wireless Analytics Ranked as 25th Fastest Growing Private Company in Massachusetts 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 3Health News:Wojo Nutrition Announces their Lines of Single Serving Liquid Vitamins will be Available for Purchase online at Abesmarket.com Beginning in May 2Health News:Comprehensive Auto Insurance Is An Important But Complex Policy 2
... supplying 150,000 HIV sufferers with free anti-retroviral drugs by the end ... on Monday . ,"We are close to 110,000 people ... of December when we launch a massive scale-up of the drugs" ... increase would be underwritten by a new batch of funding from ...
... bird flu at the weekend, taking the death toll in the ... official said Monday . ,Indonesia has seen its toll ... first confirmed human deaths occurred here. ,"A boy who ... being positively infected," Ningrum, from the ministry's National Bird Flu Information ...
... Dengue fever killed 30 people in Myanmar in the first six ... latest country in the region to experience a surge in ... ministry official, told the weekly Myanmar Times newspaper that the number ... of this year there have been about 3,000 cases of the ...
... into a skin-care product that would wipe away wrinkles and ... ,The government's team of camel researchers, which has already pioneered ... found cosmetic properties in the hardy mammal's milk. ... a hospital's skin department to study it on 20 people ...
... Scientists at Childrens National Medical Center have demonstrated conclusively ... are instrumental in myelination and remyelination, processes essential to ... , This groundbreaking discovery in mouse models ... enhance healthy brain development and/or brain disease repair in ...
... will only make real breakthroughs in childrens medicine if they ... ,Professor John Warner was speaking today at the ... solely devoted to paediatric clinical research. ,The unit ... Marys Hospital, and it is based next to the hospitals ...
Cached Medicine News:Health News:Indonesia Confirms 81st Bird Flu Death 2Health News:Specific Protein is Instrumental in Myelination 2Health News:Specific Protein is Instrumental in Myelination 3Health News:Experts Need to Include Children in Research 2
... 1-step, hand-held, point-of-care device for the qualitative detection ... The TOX/See device can detect up to ... 3 to 8 minutes and requires only a ... individually packaged to maximize convenience and ease of ...
... is a whole blood formulation designed ... of the most popular glucose meters. ... using a control matrix that closely ... packaged in ready-to-use dropper vials with ...
... the laboratory to verify automatic pipets without purchasing ... Each PVS kit contains six vials of Receiver ... Solution. Using the pipet or dilutor to be ... kit is then returned to Streck for analysis ...
... Cyto-Chex BCT is a vacuum tube ... whole blood samples for immunophenotyping by flow ... maintains the integrity of the white blood ... up to seven days. Patient samples collected ...
Medicine Products: